Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 9 min ago
PreprintAll rights reservedbioRxiv

Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy

  • S. Wang
  • Q. Xu
  • M. Wu
  • J. Duan
  • Q. Gao
  • H. Ma
  • W. Li
  • T. Zheng1
  1. 1Hangzhou Institute of Medicine, Chinese Academy of Science
Read full textPDFDOICite

Related

  1. Editorial: Chemoresistance and immunotherapy in solid tumors
    Junchao Xu
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  2. 944 Succinate-based metabolic reprogramming of innate and adaptive immunity for ovarian cancer immunotherapy
    Remya Raja, Christopher Wu, Marion Curtis +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Tumor tagging: making cold tumors visible to immunotherapy
    Tong-Yun Wang, Yue Sun, Feng Cong +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  4. 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
    Justin Moser, Igor Puzanov, Hans Hammers +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
    C.S. Voican, O. Mir, P. Loulergue +6
    Annals of OncologyPeer-reviewedLicence not statedFull text68 citedEpidemiology & public healthHAL

Cite

BibTeXRIS
BibTeX
@misc{wang2026systemic,
  title = {{Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy}},
  author = {S. Wang and Q. Xu and M. Wu and J. Duan and Q. Gao and H. Ma and W. Li and T. Zheng},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.26.754636},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.26.754636v1},
}
RIS
TY  - UNPB
TI  - Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy
AU  - S. Wang
AU  - Q. Xu
AU  - M. Wu
AU  - J. Duan
AU  - Q. Gao
AU  - H. Ma
AU  - W. Li
AU  - T. Zheng
PY  - 2026
DA  - 2026/09/26
PB  - bioRxiv
DO  - 10.64898/2026.09.26.754636
UR  - https://www.biorxiv.org/content/10.64898/2026.09.26.754636v1
ER  -